T. Rowe Price Associates Portfolio holdings
T. Rowe Price Associates, Inc., founded in 1937 by Thomas Rowe Price, Jr., is a globally recognized investment management firm headquartered in Baltimore, Maryland, known for its disciplined, research-driven approach to active investing. The company manages hundreds of billions in assets, offering a wide range of mutual funds, retirement plans, and advisory services tailored to individual investors, institutions, and financial intermediaries. Emphasizing long-term growth and a conservative investment philosophy, T. Rowe Price has built a strong reputation for its equity and fixed-income funds, often focusing on fundamental analysis to identify undervalued opportunities. Still publicly traded and independent, it remains a trusted name in the industry, balancing tradition with innovation to meet evolving client needs.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Microsoft
MSFT
|
+$3.76B |
| 2 |
Cigna
CI
|
+$1.44B |
| 3 |
Bristol-Myers Squibb
BMY
|
+$1.26B |
| 4 |
Occidental Petroleum
OXY
|
+$763M |
| 5 |
Danaher
DHR
|
+$762M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
PCYC
PHARMACYCLICS INC
PCYC
|
+$2.46B |
| 2 |
Wynn Resorts
WYNN
|
+$1.11B |
| 3 |
Netflix
NFLX
|
+$1.03B |
| 4 |
PCP
PRECISION CASTPARTS CORP
PCP
|
+$975M |
| 5 |
TWTR
Twitter, Inc.
TWTR
|
+$909M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 23.37% |
| 2 | Financials | 13.66% |
| 3 | Consumer Discretionary | 13.64% |
| 4 | Technology | 10.86% |
| 5 | Industrials | 10.79% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
NUAN
1076
DELISTED
Nuance Communications, Inc.
NUAN
| $23.6M | ﹤0.01% |
1,553,528
-365,500
| -19% | -$5.15M |
|
|
SAVE
1077
DELISTED
Spirit Airlines, Inc.
SAVE
| $23.4M | ﹤0.01% |
377,528
-18,937
| -5% | -$1.29M |
|
|
IMDZ
1078
DELISTED
Immune Design Corp.
IMDZ
| $23.3M | ﹤0.01% |
1,128,041
+426,000
| +61% | +$10.1M |
|
|
GNMK
1079
DELISTED
GenMark Diagnostics, Inc
GNMK
| $23.2M | ﹤0.01% |
2,564,554
+1,500
| +0.1% | +$15.1K |
|
|
LL
1080
DELISTED
LL Flooring Holdings, Inc.
LL
| $23.2M | ﹤0.01% |
1,121,850
+294,260
| +36% | +$7.74M |
|
1081
Helix Energy Solutions
HLX
$1.54B
| $23.2M | ﹤0.01% |
1,837,325
-420,000
| -19% | -$6.62M |
|
1082
Jack Henry & Associates
JKHY
$10.9B
| $23.1M | ﹤0.01% |
357,294
-104,551
| -23% | -$6.94M |
|
|
DNB
1083
DELISTED
Dun & Bradstreet
DNB
| $23M | ﹤0.01% |
188,425
+18,890
| +11% | +$2.43M |
|
1084
KLA
KLAC
$264B
| $22.9M | ﹤0.01% |
4,081,050
+103,000
| +3% | +$602K |
|
|
BCR
1085
DELISTED
CR Bard Inc.
BCR
| $22.8M | ﹤0.01% |
133,794
+4,900
| +4% | +$837K |
|
1086
Protolabs
PRLB
$2.17B
| $22.8M | ﹤0.01% |
337,296
+7,966
| +2% | +$562K |
|
1087
Energizer
ENR
$1.57B
| $22.6M | ﹤0.01% |
+664,512
| New | +$22.5M |
|
1088
MarketAxess Holdings
MKTX
$5.72B
| $22.5M | ﹤0.01% |
243,000
+13,700
| +6% | +$1.21M |
|
1089
Harmonic Inc
HLIT
$1.51B
| $22.5M | ﹤0.01% |
3,297,383
+10,000
| +0.3% | +$71.2K |
|
|
ILG
1090
DELISTED
ILG, Inc Common Stock
ILG
| $22.5M | ﹤0.01% |
985,497
+46,610
| +5% | +$1.18M |
|
|
BBBY
1091
DELISTED
Bed Bath & Beyond Inc
BBBY
| $22.4M | ﹤0.01% |
324,858
-6,560
| -2% | -$470K |
|
1092
Labcorp
LH
$25.9B
| $22.4M | ﹤0.01% |
215,156
+12,501
| +6% | +$1.3M |
|
1093
Lantheus
LNTH
$6.59B
| $22.4M | ﹤0.01% |
+3,619,008
| New | +$23.1M |
|
1094
Outfront Media
OUT
$5.3B
| $22.4M | ﹤0.01% |
900,542
+1,763
| +0.2% | +$48.5K |
|
|
NEWP
1095
DELISTED
NEWPORT CORP
NEWP
| $22.3M | ﹤0.01% |
1,174,190
-10,300
| -0.9% | -$200K |
|
1096
Petrobras
PBR
$115B
| $22.1M | ﹤0.01% |
2,440,352
-939,050
| -28% | -$8.4M |
|
|
STRZA
1097
DELISTED
Starz - Series A
STRZA
| $22.1M | ﹤0.01% |
493,850
+101,000
| +26% | +$4.02M |
|
|
KYNB
1098
Kyntra Bio
KYNB
$29M
| $21.9M | ﹤0.01% |
37,361
-1,736
| -4% | -$1.01M |
|
|
VAL
1099
DELISTED
Valspar
VAL
| $21.9M | ﹤0.01% |
268,275
+12,300
| +5% | +$1.03M |
|
1100
CBRE Group
CBRE
$44B
| $21.9M | ﹤0.01% |
593,205
+41,850
| +8% | +$1.59M |
|
Similar funds
T. Rowe Price Associates's Q2 2015 Portfolio in Review
As of Q2 2015, T. Rowe Price Associates held 2,615 positions worth $486B, up 0.44% from $484B the previous quarter. Its ten largest holdings account for 14% of the portfolio.
T. Rowe Price Associates's Q2 2015 filing shows 76 new, 1,051 increased, 777 reduced and 79 closed positions. Its largest new stake was Allergan plc: 548,825 shares worth $570M. The largest sale was PHARMACYCLICS INC, an estimated $2.46B.
By sector, the portfolio is most concentrated in Healthcare at 23% of assets, up from 22% a quarter earlier, followed by Financials and Consumer Discretionary.
- T. Rowe Price Associates's largest Q2 2015 buy was Allergan plc: 548,825 shares worth $570M.
- T. Rowe Price Associates added most to Microsoft in Q2 2015, an estimated $3.76B increase.
- T. Rowe Price Associates's biggest Q2 2015 reduction was Wynn Resorts, cutting an estimated $1.11B.
- T. Rowe Price Associates fully exited PHARMACYCLICS INC in Q2 2015, selling an estimated $2.46B.
- T. Rowe Price Associates's ten largest holdings make up 14% of its $486B portfolio in Q2 2015.
- T. Rowe Price Associates opened 76 new positions and closed 79 in Q2 2015.
- T. Rowe Price Associates's portfolio value rose 0.44% quarter-over-quarter to $486B.
Based on T. Rowe Price Associates's 13F filing for Q2 2015, filed 14 Aug 2015.